Juvenile Pityriasis Rubra Pilaris in a 4-year-old Child Treated Successfully with Secukinumab

Albela, Henrietta; Lee, Wai Quen; Nordin, S; Gopinathan, Lalitha P; Ramli, Muhammad N A; Leong, Kin Fon

doi:10.4103/ijd.ijd_1079_21

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several case reports and case series, PRP lesions completely or partially resolved with secukinumab, an IL-17A inhibitor (Supplemental Table S2). Skin thickness and erythema improved in a 4-year-old female with PRP after starting secukinumab 150 mg. 12 A 33-year-old woman with PRP refractory to various treatments, including ustekinumab and infliximab, experienced resolution of lesions with no recurrence after 4 weeks of secukinumab. 13 A case series of 3 male patients with PRP treated with secukinumab for 6 months experienced variable responses, with 1 patient having complete resolution of lesions, 1 experiencing partial response, and 1 having paradoxical worsening followed by partial resolution.…”

Section: Resultsmentioning

confidence: 99%

Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review

Chandy,

Chokshi,

Tan

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

Objective: To describe the published efficacy and adverse event rates associated with existing biologics for the treatment of pityriasis rubra pilaris (PRP). Data Sources: A literature review using the PubMed database (January 1990-July 2023) was conducted. Multiple search combinations were conducted using “pityriasis rubra pilaris” and various biologics as keywords to identify relevant articles. Study Selection and Data Extraction: Inclusion criteria included all study types that were published within the past 30 years in English and mentioned at least one biologic and PRP. A preliminary search yielded a total of 499 results. After screening using inclusion and exclusion criteria, 77 relevant articles (69 case reports, 5 case series, 2 clinical trials, and 1 retrospective analysis) were analyzed. Data Synthesis: TNF-α inhibitors have been evaluated and are effective in treating PRP. However, recent treatment with anti-interleukin (IL)-17 and anti-IL-23 therapies such as ustekinumab, secukinumab, and ixekizumab are emerging as new treatment options with a mean improvement in PRP Area and Severity Index scores, change in severity of erythema, scaling, and thickness of PRP lesions. From initial clinical trials, secukinumab and ixekizumab are promising treatment options for achieving remission. Relevance to Patient Care and Clinical Practice: This review compares the efficacy for numerous biologics and a discussion to guide clinicians on benefits and risks in choosing a biologic for PRP patients. Conclusions: Biologics may be a favourable treatment option leading to greater patient adherence due to reduced dosing frequencies, improvement in quality of life, and reduction in frequency and severity of flares.

show abstract

Section: Resultsmentioning

confidence: 99%